NXC 007
Alternative Names: NXC-007Latest Information Update: 11 Apr 2023
At a glance
- Originator NextGen Bioscience
- Class Antifibrotics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Pulmonary fibrosis
Highest Development Phases
- Discontinued Pulmonary fibrosis
Most Recent Events
- 11 Apr 2023 Discontinued - Preclinical for Pulmonary fibrosis in South Korea (PO)
- 25 Oct 2021 NXC 007 is available for licensing as of 25 Oct 2021. http://www.nextgenbio.co.kr/skin/page/contact01.html (NextGen Bioscience website, October 2021)
- 25 Oct 2021 Preclinical trials in Pulmonary fibrosis in South Korea (PO) before October 2021 (NextGen Bioscience pipeline, October 2021)